KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Subodh Verma, Morten Böttcher, Paul Brown, Dror Dicker, Domenica Rubino, Paolo Sbraccia, Arya M Sharma, Lærke Smedegaard, Rasmus Sørrig, W Timothy Garvey

Hypertension 83(2) e26055

PMID41328546
PMCIDPMC12822771
DOI10.1161/HYPERTENSIONAHA.125.26055
发表日期2025-12-02
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图。
摘要

摘要

BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. METHODS: The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention. Secondary and post hoc analyses evaluated the antihypertensive effect from REDEFINE 1, focusing on CagriSema and placebo groups, by subgroup/category, including baseline body mass index, the presence of hypertension or resistant hypertension at baseline, and concomitant changes in the use of antihypertensive medications. RESULTS: Overall, 3417 participants underwent randomization; CagriSema: n=2108, semaglutide: n=302, cagrilintide: n=302, and placebo: n=705. Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively). The proportion of participants reaching BP targets at week 68 was 63.0% and 32.0% for CagriSema and placebo, respectively. The proportion of participants with resistant hypertension at baseline (n=167) that reached BP targets at week 68 was 42.0% and 29.3% for CagriSema and placebo, respectively (odds ratio, 1.7 [95% CI, 0.7-4.4]). Among participants who used antihypertensive medication during the study, 39.6% in the CagriSema group decreased or stopped treatment from week 0 to week 68 versus 18.8% with placebo. CONCLUSIONS: CagriSema presents clinically relevant reductions in BP across a wide range of participant subgroups, including those with resistant hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05567796.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Change in SBP and DBP from baseline to week 68 by treatment group in the overall study population ( A and B ) and by body mass index (BMI) subgroup at baseline ( C and D ). Data are for the trial-product estimand, which assessed the effects if the trial products were taken as intended (including any of the approved doses) and was based on data from the on-treatment period. ETD indicates estimated treatment difference.
非 KM Figure
Figure 2.Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) by subgroup. Change in SBP ( A ) and DBP ( B ) from baseline to week 68 by subgroup. Data are for the trial-product estimand. Estimates of change in blood pressure obtained from a mixed model for repeated measures. Measures from the on-treatment period without rescue medication are included. N is the number of patients available for the analysis. Change represents the change from baseline to week 68. BMI indicates body mass index; eGFR, estimated glomerular filtration rate; ETD, estimated treatment difference; HbA 1c , glycated hemoglobin; and HOMA IR, Homeostatic Model Assessment for Insulin Resistance.
非 KM Figure
Figure 3.Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) by weight loss category. Change in SBP ( A ) and DBP ( B ) by category of weight loss from baseline to week 68. Estimates of change in blood pressure obtained from a mixed model for repeated measures. Measures from the on-treatment period without rescue medication are included. N is the number of patients available for the analysis. Change represents the change from baseline to week 68. Limited numbers for the placebo group preclude inclusion of data for this group (<10%, n=236; 10%–<15%, n=36; 15%–<20%, n=18%; and ≥20%, n=11).
非 KM Figure
Figure 4.Change in blood pressure from baseline to week 68 in participants classified with resistant hypertension at baseline receiving cagrilintide/semaglutide (CagriSema; n=98) or placebo (n=44). Participants were receiving ≥3 antihypertensive agents where at least 1 is a diuretic, at baseline. Estimates of change in blood pressure obtained from a mixed model for repeated measures. Measures from the on-treatment period without rescue medication are included. N is the number of patients available for the analysis. Change represents the change from baseline to week 68. DBP indicates diastolic blood pressure; ETD, estimated treatment difference; and SBP, systolic blood pressure.
非 KM Figure
Figure 5.Change in hypertension medications from baseline to week 68 in participants receiving hypertension medication during the trial. Data are for the treatment-policy estimand from the in-trial period for participants receiving antihypertensive medication between baseline to week 68 with data available at the end of the on-treatment period.
非 KM Figure